- Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. Collette, L., Burzykowski, T., Carroll, K.J., Newling, D., Morris, T., Schröder, F.H. J. Clin. Oncol. (2005)